- Home
- QSI vs EYPT Comparison
QSI vs EYPT Comparison
Compare QSI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- EYPT
- Stock Information
- Founded
- QSI 2013
- EYPT 1987
- Country
- QSI United States
- EYPT United States
- Employees
- QSI N/A
- EYPT N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- QSI Health Care
- EYPT Industrials
- Exchange
- QSI Nasdaq
- EYPT Nasdaq
- Market Cap
- QSI 633.2M
- EYPT 594.5M
- IPO Year
- QSI N/A
- EYPT 2005
- Fundamental
- Price
- QSI $1.93
- EYPT $7.75
- Analyst Decision
- QSI Buy
- EYPT Strong Buy
- Analyst Count
- QSI 2
- EYPT 8
- Target Price
- QSI $3.25
- EYPT $25.71
- AVG Volume (30 Days)
- QSI 56.4M
- EYPT 890.4K
- Earning Date
- QSI 02-27-2025
- EYPT 03-06-2025
- Dividend Yield
- QSI N/A
- EYPT N/A
- EPS Growth
- QSI N/A
- EYPT N/A
- EPS
- QSI N/A
- EYPT N/A
- Revenue
- QSI $2,266,000.00
- EYPT $45,713,000.00
- Revenue This Year
- QSI $193.90
- EYPT N/A
- Revenue Next Year
- QSI $173.18
- EYPT N/A
- P/E Ratio
- QSI N/A
- EYPT N/A
- Revenue Growth
- QSI 232.26
- EYPT 7.50
- 52 Week Low
- QSI $0.61
- EYPT $6.90
- 52 Week High
- QSI $5.77
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- QSI 46.00
- EYPT 44.95
- Support Level
- QSI $2.30
- EYPT $6.91
- Resistance Level
- QSI $5.77
- EYPT $9.50
- Average True Range (ATR)
- QSI 0.83
- EYPT 0.59
- MACD
- QSI -0.08
- EYPT 0.16
- Stochastic Oscillator
- QSI 15.97
- EYPT 32.69
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.